White matter (WM) lesions, characterized by the loss of myelin and myelin-producing oligodendrocytes (OLs), are a major cause of functional disability after stroke but have not been widely appreciated in therapeutic studies until recently. Here we propose to rectify this gap in the field by focusing on WM integrity and its modulation by immune responses in the ischemic brain. Activated microglia/macrophages of distinct phenotypes are known to determine OL cell fate and WM integrity after brain injuries. Specifically, the alternatively activated M2 phenotype is essential for WM preservation and repair because M2 cells resolve local inflammation, clear broken myelin sheaths, and provide trophic factors that promote WM repair. CD4+CD25+ regulatory T cells (Tregs) are a specialized subpopulation of T cells that negatively regulate immune responses. Our recent study demonstrated that adoptive Treg therapy exerted early neuroprotection by targeting inflammatory dysregulation and neurovascular disruption after stroke. However, it is not known whether Tregs also have a beneficial effect on WM integrity. Recently, we discovered that Treg-conditioned media stimulates microglial polarization toward the M2 phenotype, and M2 microglia enhance OL survival and promote OPC differentiation in vitro. These exciting results suggest that Tregs can preserve WM integrity. We obtained further promising data showing that 1) Treg transfer at 2h of reperfusion reduced the extent of WM injury and improved sensorimotor functions for at least 28d after transient middle cerebral artery occlusion (tMCAO); 2) Post-stroke Treg treatment resulted in a long-lasting elevation of IL-10, a major Treg-derived cytokine that is important for WM repair; 3) Treg treatment promoted M2 polarization of microglia/macrophages in both WM and gray matter after tMCAO. Furthermore, we have successfully induced a robust increase of Tregs in the circulation after stroke by systemic injection of interleukin (IL)-2/IL-2 antibody complex (IL-2/IL- 2Ab), an established approach to expand Tregs in vivo. We demonstrated that IL-2/IL-2Ab-induced Treg expansion reduces myelin loss 7d after tMCAO and improves sensorimotor functions. The current proposal will further explore the effects of Tregs on WM injury and repair after stroke and develop in vivo Treg expansion as a novel strategy to promote WM integrity and enhance post-stroke recovery. The central hypothesis to be tested is that Tregs promote WM integrity and long-term recovery after stroke by polarizing microglia/macrophages toward the M2 phenotype in an IL-10 dependent manner.
Three specific aims are proposed:
Aim 1. Test the hypothesis that Treg treatment after stroke improves long-term functional recovery and promotes WM integrity.
Aim 2. Test the hypothesis that Treg-derived IL-10 shifts microglia/macrophage polarization towards the M2 phenotype, thereby promoting WM integrity after stroke.
Aim 3. Test the hypothesis that in vivo expansion of Tregs with post-stroke IL-2/IL-2Ab treatment is effective in reducing long-term WM injury and improving neurological recovery after stroke.

Public Health Relevance

Recent research highlights the importance of immune responses in post-stroke brain injury and recovery. This proposal will test the hypothesis that regulatory T cells (Tregs) improve long-term neurological outcomes after ischemic stroke by promoting microglia/macrophage polarization towards the M2 phenotype (a phenotype that is able to resolve local inflammation and facilitate tissue repair) and therefore enhancing the integrity of injured white matter. Positive results from this proposal may help identify a potentia immunotherapy for the prevention of long-term disability after stroke.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
5R01NS094573-02
Application #
9237323
Study Section
Acute Neural Injury and Epilepsy Study Section (ANIE)
Program Officer
Bosetti, Francesca
Project Start
2016-03-15
Project End
2021-01-31
Budget Start
2017-02-01
Budget End
2018-01-31
Support Year
2
Fiscal Year
2017
Total Cost
$303,187
Indirect Cost
$106,312
Name
University of Pittsburgh
Department
Neurology
Type
Schools of Medicine
DUNS #
004514360
City
Pittsburgh
State
PA
Country
United States
Zip Code
15213
Zhang, Haiyue; Xia, Yuguo; Ye, Qing et al. (2018) In Vivo Expansion of Regulatory T Cells with IL-2/IL-2 Antibody Complex Protects against Transient Ischemic Stroke. J Neurosci 38:10168-10179
Hu, Xiaoming; Leak, Rehana K; Thomson, Angus W et al. (2018) Promises and limitations of immune cell-based therapies in neurological disorders. Nat Rev Neurol 14:559-568
Li, Peiying; Wang, Long; Zhou, Yuxi et al. (2017) C-C Chemokine Receptor Type 5 (CCR5)-Mediated Docking of Transferred Tregs Protects Against Early Blood-Brain Barrier Disruption After Stroke. J Am Heart Assoc 6:
Yang, Yuanyuan; Liu, Huan; Zhang, Haiyue et al. (2017) ST2/IL-33-Dependent Microglial Response Limits Acute Ischemic Brain Injury. J Neurosci 37:4692-4704
Cai, Wei; Liu, Huan; Zhao, Jingyan et al. (2017) Pericytes in Brain Injury and Repair After Ischemic Stroke. Transl Stroke Res 8:107-121
Liu, Huan; Yang, Yuanyuan; Xia, Yuguo et al. (2017) Aging of cerebral white matter. Ageing Res Rev 34:64-76
Mao, Leilei; Li, Peiying; Zhu, Wen et al. (2017) Regulatory T cells ameliorate tissue plasminogen activator-induced brain haemorrhage after stroke. Brain 140:1914-1931
Xia, Yuguo; Cai, Wei; Thomson, Angus W et al. (2016) Regulatory T Cell Therapy for Ischemic Stroke: how far from Clinical Translation? Transl Stroke Res 7:415-9